soul trial oral semaglutide cardiovascular outcomes 2024 results nejm Editorial Fellow Harleen Marwah, MD, summarizes the trial. Visit NEJM.org for the full results. #ACC25 #Cardiology #ClinicalTrials #MedTok #NEJM Effects of oral semaglutide on
Pay in 4 interest-free payments of $7.33 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 1 - Aug 6
Live Spec
Effects of oral semaglutide on cardiovascular outcomes in individuals with type 2 diabetes and established atherosclerotic cardiovascular disease and or chronic kidney disease: Design and baseline characteristics of SOUL, a randomized trial Frontiers Cardiovascular Safety and Benefits of Semaglutide in Patients With Type 2 Diabetes: Findings From SUSTAIN 6 and PIONEER 6 Oral Semaglutide and Cardiovascular Outcomes in Type 2 Diabetes New England Journal of Medicine SELECT Trial Oral Semaglutide Reduces CV Events in T2DM SOUL Trial (NEJM, Mar 2025) Relevant for: cardiology, diabetology, nephrology, internal medicine T2DM + ASCVD CKD Oral semaglutide 14 mg vs placebo Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes New England Journal of Medicine
Store: lestom-kurzy.sk · Domain: lestom-kurzy.sk





























